A cute traumatic coagulopathy (ATC, also known as traumainduced coagulopathy) is common, affecting one in three severely injured patients. 1, 2 Since its discovery, the trauma community has sought to characterize the underlying physiologic mechanisms and optimal treatment of this disease. Treatment strategy for the injured coagulopathic patient typically consists of plasma-based balanced resuscitation, 3 but there are no validated patient-specific algorithms specifying how to tailor administration to different patterns of standard coagulation values. Despite significant advances, coagulopathy portends worse outcomes and increased mortality for affected patients. 2, 4, 5 One potential cause underlying this ongoing morbidity may be that ATC is not a single entity but is actually composed of multiple coagulopathic phenotypes that warrant distinct, targeted treatment strategies.
The hematology community recognizes multiple distinct defects in coagulation leading to heritable and acquired coagulopathy. Often, discordance between standard measurements on routine coagulation testing suggests pathology driven by pathway-specific factor deficiencies. 6, 7 Diagnosis ensues, and treatment is then tailored to the specific factor deficit. Although these disorders in most cases are reflective of single derangements in coagulation as opposed to the multifactorial disordered mechanisms underlying ATC, this approach highlights the contrast to the diagnostic and treatment practice used in hemostatic resuscitation. While patients with other hematologic disorders receive a diagnosis and treated to target specific abnormalities, even in the era of "precision medicine" traumatic coagulopathy is commonly considered as a single disease and treated in a nontargeted manner despite voluminous revolutionary work in coagulation and hemostatic resuscitation.
Although some centers now utilize thromboelastography parameters to diagnose traumatic coagulopathy, ATC was originally defined as admission prolongation of either prothrombin time/international normalized ratio (INR) or activated partial thromboplastin time (PTT), 1, 2 and these tests remain the most widely available and continue to be commonly utilized today. However, PTT and INR evaluate separate physiologic pathways that (if functioning appropriately) ultimately result in fibrin generation, and while some patients with coagulopathic trauma present with prolongation of both, many demonstrate isolated elevation of either PTT or INR. 2, 8 International normalized ratio assesses patient response to tissue factor exposure, traditionally referred to as the "intrinsic" coagulation pathway. This pathway relies on sufficient levels of functioning factor VII to induce "common" pathway activation and eventual thrombin production. 9 Partial thromboplastin time evaluates the contact activation pathway (formerly "extrinsic" pathway), measuring the response of blood to an activator, which triggers sequential activation of a series of mediators including factors XII, XI, IX, and VIII, culminating in "common pathway" activation. 10 Deficiency in mediators of the "common" pathway including factors V, X, or II can also lead to prolongation of both PTT and INR.
Differences in the coagulation profiles of patients presenting with ATC compared with noncoagulopathic patients have been previously described and include relative deficiencies of factors II, V, VII, VIII, IX, and X; activation of protein C (PC); and elevated D-dimer. 8, 11, 12 However, the extent to which injuries, factor profiles, and outcomes differ in patients presenting with discordant abnormalities in standard tests remains unknown and may suggest critical, targetable differences in pathology. The purpose of this study was to define phenotypes of ATC. Specifically, we sought to identify patient and injury patterns that drive isolated prolongations of PTT, INR, or the combination of both and to characterize the detailed coagulation profile specific to each pattern. We hypothesized that isolated PTT prolongation, isolated INR prolongation, and dual PTT and INR prolongation after trauma represent distinct "coagulation phenotypes" driven by abnormality of one or more pathway-specific composite factors, which may provide potential targets for tailored resuscitation of the injured coagulopathic patient.
METHODS
Admission plasma samples were prospectively collected from 1,262 adult patients who met criteria for highest-level trauma activation at a single, urban Level In addition to standard coagulation measures, samples were assayed for an extensive panel of procoagulant and anticoagulant factors including PC, D-dimer, antithrombin III (ATIII), and factors II, V, VII, VIII, IX, and X using a Stago-Compact Functional Coagulation Analyzer (Diagnostica Stago, Parsippany, NJ). Although the study was initiated prior to availability of functional testing at our institution, samples collected after March 2010 were also assayed using ROTEM Delta System Analyzer, Model ET1729L, to assess clot function in the presence of tissue factor alone (EXTEM) and with platelet inhibitor cytochalasin D (FIBTEM). EXTEM maximal clot firmness (MCF) was used as a measurement of overall functional coagulability, whereas FIBTEM MCF was used to measure the functional contribution of fibrin polymerization to clot formation.
Demographics, resuscitation data, laboratory results, and outcomes were collected and matched to coagulation profiles for each patient. Data collected included demographic information (age, gender, body mass index), injury characteristics (mechanism, injury severity as measured by Injury Severity Score [ISS], 13 Glasgow Coma Scale [GCS] score 14 ), physiologic and laboratory data (temperature, base deficit, platelet count, fibrinogen, transfusion of packed red blood cells [PRBCs] , plasma [fresh frozen plasma {FFP}], platelets within the first 72 hours of admission), and hospital-related outcomes ("ventilatorfree" days, multiple organ failure, and death). Multiorgan failure was defined using the Denver Post-injury Multiple Organ Failure Score. 15 Descriptive statistics are reported as means and SDs for normally distributed data and medians with interquartile ranges for skewed and ordinal data. Binary variables are described with percentages. Differences between groups were evaluated using χ 2 and Fisher exact test for proportions and categorical variables, Student t test or one-way analysis of variance for normally distributed data, and Wilcoxon rank-sum or Kruskal-Wallis one-way analysis of variance for ordinal data and variables with nonparametric distributions.
Univariate and multiple linear regressions were used to further assess relationships between coagulopathic phenotype and differentially expressed coagulopathic markers and transfused blood products. Kaplan-Meier survival analysis was used to generate time-to-death curves stratified by coagulopathic phenotype. An α < 0.05 was considered significant for all analyses. Statistical analysis was performed using Stata 14 (StataCorp, College Station, TX).
RESULTS

Coagulopathic Versus Noncoagulopathic Patients
Of 1,262 eligible patients, 14% (181 patients) presented with coagulopathy. Consistent with the reports of other investigators, the coagulopathic patients in our cohort demonstrated significant differences in patient and injury characteristics, coagulation profiles, and worse outcomes compared with noncoagulopathic patients (Table 1) .
Coagulopathic Phenotypes Demographics and Injury Characteristics
Among patients with admission coagulopathy, 9% (17 patients) presented with isolated elevated INR (INR-TF), 43% (77 patients) presented with isolated prolonged PTT (PTT-CONTACT), and 48% had abnormal INR and PTT (BOTH). Elevated PTT groups (PTT-CONTACT and BOTH) had lower GCS score than did the INR-TF patients. These groups also trended toward increased injury severity, but this was not statistically or clinically significant. There were no other differences in patient demographics or injury characteristics between coagulopathic phenotypes (Table 2) .
Coagulation Profile
Coagulopathic phenotype groups demonstrated differences in factor activity levels consistent with their specific coagulation activation pathways (Fig. 1) . The INR-TF and BOTH patients had decreased factor VII activity compared with PTT-CONTACT. Patients with perturbations in the contact pathway (BOTH and PTT-CONTACT) had decreased admission factor VIII activity compared with INR-TF. There were no significant differences in factor IX between groups (p = 0.571) (Fig. 1 ). All coagulopathic patients had critically depressed common pathway factor V activity, but levels were lowest in BOTH. There were no significant differences between the coagulopathic groups for common pathway factor II or X activity. Unadjusted and multiple linear regression of coagulopathic group on factor levels confirmed these patterns (see Table, Coagulopathic phenotypes also demonstrated differential expression of fibrinogen, D-dimer, ATIII, and PC (Fig. 2) . Fibrinogen levels were highest for PTT-CONTACT, lower for INR-TF, and lowest for BOTH. D-Dimer was elevated in PTT-CONTACT and BOTH compared with INR-TF. Antithrombin III activity was lowest in the BOTH phenotype. Finally, PC was lower in elevated INR phenotypes compared with PTT-CONTACT. Univariate and multiple linear regressions of coagulopathic phenotypes on these markers revealed similar prediction patterns with the following exceptions: (1) only BOTH predicted significant decrease in fibrinogen levels on univariate and multiple regressions, and (2) BOTH and PTT-CONTACT predicted decrease in ATIII on univariate regression; however, only BOTH predicted ATIII depression on multiple regression analysis (see Tables, SDCs 2 Functional measures of overall coagulability (EXTEM MCF) and fibrin polymerization (FIBTEM MCF) were depressed in patients with BOTH relative to INR-TF and PTT-CONTACT (Table 2) .
Transfusion Requirements
There were disparities in product transfusion between coagulopathic phenotypes (Fig. 3) . The PTT-CONTACT group received less PRBCs and FFP than did other groups at 24 and 72 hours. Similar relationships between phenotype and product transfusion were predicted by univariate and multiple linear regressions (see Tables, SDCs 6 and 7, http://links.lww.com/ TA/A916). In fact, PTT-CONTACT did not statistically predict PRBC transfusion at either time point in multiple linear regression. The PTT-CONTACT group also received the fewest platelet units of any phenotype at 24 hours (p = 0.040), but no statistical difference between phenotypes was seen for platelet transfusion at 72 hours (p = 0.087).
Outcomes
There were no differences in ventilator-free days or multiorgan system failure between phenotypic groups ( Table 2) . Twenty-four-hour and discharge mortality was lowest for INR-TF, higher for PTT-CONTACT, and highest for BOTH (Table 2 ). In Kaplan-Meier survival analysis adjusted for injury severity, estimated survival rates were again highest for INR-TF, lower for PTT-CONTACT, and lowest for BOTH with statistical difference between curves (Fig. 4) .
DISCUSSION
Acute traumatic coagulopathy is common after severe injury and contributes to increased bleeding, mortality, and poor outcomes in survivors. 2, 8, 11, 12 Considerable work toward mechanistic characterization has ensued since ATC was first described, yet despite better understanding, the ability to diagnose separate phenotypes and apply targeted treatment remains limited in practice. 8, 11, 12 Hemostatic resuscitation has focused on one-size-fits-all, plasma-based resuscitation protocols. These protocols have resulted in considerable mortality reductions; however, in the age of precision medicine, we have the opportunity to further improve outcomes by individualizing diagnosis and applying targeted treatment.
Recent prospective, randomized data from the Denver Health group have demonstrated that utilizing functional testing to guide resuscitation for patients with severe injuries and physiologic collapse led to decreased mortality compared with guidance based on conventional testing. 16 These data provide support for the idea that ATC is not simply a single entity and is a perfect example of the efficacy of shifting toward a paradigm of individualizing care to patient physiology. However, abnormal PTT was not utilized as one of the conventional criteria for resuscitation, which, in light of the data presented here, may have significantly contributed to higher mortality in the conventional assay group. We propose that the optimal, precision approach would include an understanding of the biologic underpinnings of all commonly collected assays, with integration of this information in order to best target individualized treatment.
In this prospective observational cohort, we provide the first evidence that conventional assay phenotypes provide specific mechanistic information with the potential to inform and tailor resuscitation presenting with coagulopathy. Discordant standard coagulation assays INR-TF versus PTT-CONTACT versus BOTH have different associated demographic and injury patterns and Simplified schematic of the coagulation cascade highlighting points of differential factor activity between coagulopathic phenotypes. **Significant differences between groups at an α level p < 0.05. TF indicates tissue factor; II, factor II; V, factor V; VII, factor VII; VIII, factor VIII; IX, factor IX; X, factor X. different outcomes. The INR-TF phenotype occurs in patients with preserved admission GCS score and demonstrates a coagulopathic profile marked by low PC and depressed factor VII activity. The PTT-CONTACT phenotype is characterized by low initial GCS score and a coagulopathic profile notable for relative factor VIII deficiency with preserved PC and elevated D-dimer. Patients with PTT-CONTACT coagulopathy received less PRBC and FFP resuscitation than did the patients with other phenotypes but demonstrated high mortality rates. Finally, the BOTH phenotype appears to demonstrate the most severe coagulopathy and highest mortality after injury. The BOTH phenotype is characterized by depressed GCS score at admission, with a coagulopathic profile significant for a combination of depressed factor VII and factor VIII, critically deficient factor V, low fibrinogen and ATIII, and elevated D-dimer.
These differences provide insight into potential targets for treatment beyond the standard balanced plasma-based resuscitation. 
Demographics and Injury Characteristics
The association between depressed GCS score and elevated PTT phenotypes provides indirect evidence that traumatic brain injury may play a role in perturbation of the contact activation pathway. Early post-TBI coagulopathy has canonically attributed to consumptive coagulopathy in the tissue factor pathway following tissue factor release from damaged brain tissue. 17 However, we demonstrate that low GCS score is associated with prolonged PTT even without concomitant INR derangement, suggesting that TF pathway consumption does not fully explain post-TBI coagulopathy. Other research has also questioned the primacy of the tissue-factor-release hypothesis. 18, 19 Of course, low GCS score is not a perfect surrogate for brain injury, highlighting the need to examine coagulopathic phenotypes specifically in a TBI population. Improved understanding of the mechanisms underlying post-TBI coagulopathy could ultimately provide the basis for a targeted approach to preventing progression of intracranial hemorrhage.
Implications of Coagulation Profile Differences
Differentially expressed coagulation markers provide insight into the mechanistic differences between coagulopathic phenotypes and more importantly may suggest potential targets for tailored resuscitation practice. Our data suggest that depressed factor VII activity drives perturbations of the tissue factor activation pathway after injury and consequently can provide a potential target for attenuating ATC in this subgroup. Use of activated recombinant factor VII initially received considerable attention but was never broadly accepted by the trauma community because of multiple studies suggesting questionable efficacy in prevention of mortality and increased thrombosis. 20, 21 In the majority of these studies, recombinant factor VII was used in patients undergoing massive transfusion at late stages in their coagulopathic course, rather than targeted toward patients with elevated INR on admission. 22 While the present study does not provide sufficient evidence to recommend empiric factor VII administration, we do suggest that prospective phenotypic-specific repletion warrants further investigation. Although factor VIII levels are known to be elevated following severe injury, 23 patients with PTT elevation coagulopathy uniquely demonstrate relative depressions in median factor VIII activity compared with noncoagulopathic patients. 8 This has several interesting implications for resuscitation. First, while in healthy controls factor activity levels of 30% are commonly accepted as sufficient for adequate coagulation, the natural history and sufficient factor levels for functional clotting after injury have never been delineated. These data suggest that higher-than-expected levels of functional factor VIII may be necessary for adequate coagulation in the trauma setting. Furthermore, abnormalities in the contact activation pathway may be driven by relative deficits in factor VIII activity. Interestingly, this association is found in PTT-CONTACT despite relatively preserved PC levels (low activated PC [aPC]). Although aPC is known to down-regulate factors V and VIII, 11 our data suggest that factor VIII depletion in PTT-CONTACT may occur via another mechanism or, alternatively, that even low amounts of aPC activity are sufficient to down-regulate factor VIII to levels insufficient for posttrauma hemostasis. Of note, factor VIII levels in BOTH are even lower than in PTT-CONTACT, which may be attributable to a combination of mechanisms including exacerbation of the inhibitory influence of aPC, which is elevated in BOTH. Early targeted repletion of factor VIII in patients with elevated PTT phenotypes may correct perturbations in this pathway and prevent coagulopathy from worsening. Fresh frozen plasma, the primary product utilized in the current treatment of coagulopathy, tends to have relatively low levels of factor VIII 24 and does not provide an ideal source for repletion. Critical factor V deficiency was present in all coagulopathic groups. We hypothesize that dual perturbation of contact and tissue factor activation pathways with deficits of multiple pathway mediators resulted in additive downstream depression resulting in the most severe deficiencies among patients in the BOTH cohort. However, factor V repletion represents an important resuscitation target for all coagulopathic groups, which may partially explain the efficacy of FFP in the treatment of traumatic coagulopathy. These data provide mechanistic evidence that all coagulopathic groups likely will continue to derive benefit from FFP resuscitation, although, as suggested previously, additional adjuncts may be necessary to adequately treat other, phenotype-specific, factor deficiencies. In addition, this implicates the potential utility of aPC pathway inhibition.
Fibrinogen deficit also appeared to be most severe in the setting of dual-contact and tissue factor activation abnormality. Of note, admission fibrinogen levels in BOTH approached traditional thresholds for transfusion; therefore, we would advocate maintaining a high index of suspicion for hyperfibrinolysis among patients presenting with BOTH and trending fibrinogen closely throughout early resuscitation in this population with repletion as necessary, particularly in situations where functional assays are unavailable.
Antithrombin III is a key regulator of endogenous anticoagulation. Antithrombin III activity deficit is known to correlate with increasing injury severity, 25 which largely accounts for the low ATIII seen in patients with ATC. However, when adjusted for GCS score and injury severity, only dual perturbation of contact and tissue factor pathways remains associated with depressed ATIII. Patients presenting with ATC are known to have increased rates of thrombotic complications throughout hospitalization. 26 Further investigation is needed to determine whether presentation with BOTH phenotype specifically portends increased, potentially modifiable, thrombotic risk. This deficit may underscore the necessity of aggressive and early FFP resuscitation in this group.
Finally, PC correlates inversely with aPC, a key driver of ATC, which functions, in part, via inactivation of factors V and VIII. 11 Our data suggest that aPC, which is highest among elevated INR phenotypes, may play a substantial role in dysregulation of the tissue factor activation pathway. This observation provides clinical corroboration for recent research demonstrating attenuation of aPC following tissue factor pathway inhibition in a murine model. 27 
Functional Testing
Among all admission functional testing, only FIBTEM MCF for the BOTH phenotype reached the manufacturer's threshold for hypocoagulability, which may partially be attributable to the lack of validated ROTEM cutoffs in the trauma population. However, as described previously, the coagulopathic groups identified by standard coagulation tests were deficient in multiple coagulation markers and demonstrated clinical coagulopathy including higher transfusion requirements and worse outcomes compared with the noncoagulopathic patients. Although as previous studies have suggested many coagulopathic patients will share both abnormal ROTEM and traditional coagulation tests, our data suggest that these assays may not infrequently identify different subsets of patients with coagulopathy, suggesting that they should be used concomitantly to best direct diagnosis and targeted treatment.
Outcomes
Product resuscitation differed between coagulopathic phenotype groups, with preferential PRBC and FFP resuscitation for phenotypes presenting with some component of elevated INR coagulopathy. It is possible that PTT-CONTACT patients did not receive as many PRBCs because these patients achieved earlier hemostasis; unfortunately, the present study did not collect information regarding blood loss or surgical hemostasis. However, particularly in consideration of the high early mortality rates for this group, we suspect that PTT-CONTACT patients were substantially underresuscitated compared with those with INR abnormalities.
Mortality rates differed considerably between coagulopathic phenotypes and were lowest for INR-TF, higher for PTT-CONTACT, and highest for BOTH throughout admission. Kaplan-Meier survival analysis of death demonstrated a similar pattern for survival rates among coagulopathic phenotypes after adjustment for injury severity. While it is important to recognize that death is a highly complex outcome with multiple interacting predictors, it is highly unlikely that the cause of death in these patients is solely or primarily attributable to ATC. However, these data do provide evidence that these phenotypes play a significant, if incomplete, role in survival. All phenotypes were predicted to have decreased survival compared with noncoagulopathic patients, emphasizing the need for improved, individualized treatment strategies after injury.
Limitations
Limitations of this study include those inherent to observational study design and a single-center cohort and highlight the utility for further prospective investigations regarding the implications of coagulopathic phenotypes among the broader trauma community. The power of our statistical analysis was limited by a relatively small number of coagulopathic patients. Furthermore, the cutoffs for coagulopathy were selected according to thresholds previously described in the literature, but we recognize that they are not absolute, and different cutoffs could be selected. We would hypothesize that with more extreme thresholds coagulation factor deficits, transfusion requirements, and even higher mortality would be expected. Finally, we recognize that while this article focuses on phenotypes delineated by standard coagulation testing there are other variables that play key roles in coagulopathic physiology including platelet function and fibrinolysis, which were not investigated here. It is also possible that additional key explanatory variables exist, which are important to the understanding of coagulopathic phenotype but which were not measured in this study.
CONCLUSIONS
We demonstrate that patients with a diagnosis of ATC comprise distinct coagulopathic phenotypes, which can be characterized by discordance in standard coagulation assays. These phenotypes demonstrate distinct biologic profiles that recommend pathway-specific potential treatment targets, which could be potentially used in a precision medicine approach to treatment of coagulopathy. We propose the need for additional prospective investigation to address the efficacy of phenotypespecific therapy for the treatment of traumatic coagulopathy. Through the recognition of the physiology and implications of distinct, readily diagnosable coagulopathic groups within the overarching disease of ATC, clinicians have the opportunity to expand the arsenal of individualizing risk assessment and make informed, mechanistically grounded decisions regarding treatment. 
